BBI Split History

BBI (BBI) has 2 splits in our BBI split history database. The first split for BBI took place on September 03, 2019. This was a 1 for 7 reverse split, meaning for each 7 shares of BBI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split. BBI's second split took place on July 05, 2022. This was a 1 for 45 reverse split, meaning for each 45 shares of BBI owned pre-split, the shareholder now owned 1 share. For example, a 142.857142857143 share position pre-split, became a 3.17460317460317 share position following the split.

When a company such as BBI conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the BBI split history from start to finish, an original position size of 1000 shares would have turned into 3.17460317460317 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BBI shares, starting with a $10,000 purchase of BBI, presented on a split-history-adjusted basis factoring in the complete BBI split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	12/04/2012
End date:	09/07/2022
Start price/share:	$948.15
End price/share:	$2.35
Dividends collected/share:	$0.00
Total return:	-99.75%
Average Annual Total Return:	-45.92%
Starting investment:	$10,000.00
Ending investment:	$24.77
Years:	9.76

About BBI

Brickell Biotech is a clinical-stage pharmaceutical company focused on the development of prescription therapeutics for the treatment of debilitating skin diseases with a focus on its main asset for the treatment of hyperhidrosis. Co.'s investigational product candidate, sofpironium bromide, is a chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Co. is developing sofpironium bromide in the U.S. for the treatment of primary axillary hyperhidrosis. According to our BBI split history records, BBI has had 2 splits.